Forbes reports that Tesaro--a 2011 Fierce 15 company--has just in-licensed the cancer drug niraparib from Merck ($MRK). The therapy fits into a new class of cancer drugs called PARP inhibitors, with potential to treat ovarian and breast cancers. A number of Big Pharma companies have been spinning off programs that no longer fit within their revised pipeline strategies. And Tesaro, which was launched by a group of veterans from MGI Pharma, thinks it can benefit from the trend. Story